swi019
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 14, 2020 (NCT04450069)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Burkitt Lymphoma · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lupus Erythematosus, Systemic · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Myositis · Phase 1
- Sclerosis · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06913608 | Phase 1 | May 31, 2025 | California Institute for Biomedical Research |
| NCT04488354 | Phase 1 | Jan 21, 2021 | California Institute for Biomedical Research, University of California, San Diego |
| NCT04450069 | Phase 1 | Aug 14, 2020 | California Institute for Biomedical Research, University of California, San Diego |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| California Institute for Biomedical Research | Academic/Hospital | 3 | 3 | 1 | 2020 |
| University of California, San Diego | Academic/Hospital | 2 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1